(Q34313648)

1 August 2017

title

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas (English)

1 reference

1 August 2017

13

Jorge Lima

1 reference

1 August 2017

Joana Peixoto

5

0 references

Margarida M Moura

Margarida Moura

17

0 references

Catarina Salgado

Catarina Salgado

9

0 references

Adriana Gaspar da Rocha

Adriana Gaspar da Rocha

2

0 references

Rui Batista

Rui Batista

4

0 references

Hugo Prazeres

Hugo Prazeres

12

0 references

Patrícia Castro

Patrícia Castro

11

0 references

Miguel Melo

Miguel Melo

1

0 references

Ricardo Celestino

Ricardo Celestino

7

0 references

Branca M. Cavaco

Branca Cavaco

18

0 references

João Vinagre

João Vinagre

3

0 references

Valeriano Leite

Valeriano Leite

19

0 references

Catarina Eloy

Catarina Eloy

10

0 references

Manuel Sobrinho Simões

Manuel Sobrinho-Simões

24

0 references

Paula Soares

Paula Soares

25

0 references

Cláudia Lobo

15

Cláudia Lobo

1 reference

José Manuel Cameselle-Teijeiro

1 August 2017

20

José Manuel Cameselle-Teijeiro

1 reference

1 August 2017

21

Francisco Carrilho

1 reference

1 August 2017

23

Valdemar Máximo

1 reference

1 August 2017

Catarina Tavares

6

1 reference

1 August 2017

Ana Almeida

8

1 reference

1 August 2017

Teresina Amaro

14

1 reference

1 August 2017

Maria João Martins

16

1 reference

1 August 2017

Manuela Carvalheiro

22

1 reference

1 August 2017

language of work or name

English

0 references

publication date

29 January 2014

1 reference

The Journal of Clinical Endocrinology and Metabolism

1 August 2017

published in

1 reference

1 August 2017

volume

99

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

E754-65

1 reference

The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Frequency of TERT promoter mutations in human cancers

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Highly prevalent TERT promoter mutations in aggressive thyroid cancers

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

DNA microarray and miRNA analyses reinforce the classification of follicular thyroid tumors.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Highly recurrent TERT promoter mutations in human melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

TERT promoter mutations in familial and sporadic melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Accessories to the crime: functions of cells recruited to the tumor microenvironment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Expression of telomerase genes in thyroid carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

6 July 2018

The Hallmarks of Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

A survey of telomerase activity in human cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Telomere elongation in immortal human cells without detectable telomerase activity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Growth factors controlling the thyroid gland

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Strategies of radioiodine ablation in patients with low-risk thyroid cancer

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancer.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4191548

Telomerase activity in human thyroid carcinomas originating from the follicular cells

28 October 2018

1 reference

12 December 2020

BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC

1 reference

12 December 2020

Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer

1 reference

12 December 2020

Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications

1 reference

12 December 2020

Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines

1 reference

12 December 2020

Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo

1 reference

12 December 2020

Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness

1 reference

12 December 2020

BRAFMutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas

1 reference

12 December 2020

Identifiers

DOI

10.1210/JC.2013-3734

1 reference

1 August 2017

1 reference

1 August 2017

1 reference